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The current status ofantiviral therapy is reviewed, including discussion of older approaches together with
more recently developed chemotherapy. Following the introduction dealing with pathophysiological aspects
ofvirus disease, the different approaches to antiviral therapy are presented. The reasons forthe slow progress
in antiviral therapy are discussed. These include: 1. the necessity of intracellular penetration ofdrugs acting
on viral replication; 2. the severe toxicity ofmost antiviral drugs; 3. the narrow antiviral spectrum ofmost of
these agents; 4. the difficulty of making a rapid etiological diagnosis in view of the necessity of starting
(specific?) treatment early in the course ofthe disease; 5. thedifficult evaluation ofbeneficial as compared with
deleterious effects of antiviral therapy. After a detailed review of clinically tested substances, including
immunoglobulins, synthetic antiviral drugs (amantadine, nucleoside analogs, thiosemicarbazones and pho-
todynamic dyes) and interferon, a guide concerningindications and application ofspecific antiviral therapy is
presented. Although at present there are few indications, clinicians should be aware of the (present and
future) possibilities of antiviral therapy.
INTRODUCTION
Considering the remarkable progress made in antibacterial therapy in the past
three decades, the advances made in specific treatment of viral disease have been
disappointingly slow. So far there are only a small number of antiviral agents which
are useful in a restricted number of clinical situations. Furthermore, most antiviral
drugs do not selectively inhibit virus replication without simultaneously injuring the
host cell, and are therefore accompanied by serious side effects. Thus, possible
beneficial effects of antiviral drugs must be balanced against potential immunosup-
pressive and other undesirable side effects. Nevertheless, the physician, faced with a
seriously ill patient or concerned about the individual and economic consequences of
an incipient epidemic of viral disease, is under considerable pressure by the patient,
by the public or by his colleagues, to apply antiviral therapy. Although the pharma-
cology and use of antiviral drugs has recently been reviewed [1-6] an overall
reassessment of antiviral therapy, considering older approaches, such as postexpo-
sure immunization, along with the newer chemotherapy, is lacking. This review
attempts to fill this gap: in the first section the pathophysiology oftypical viral disease
will be briefly described permitting a rational approach to antiviral therapy. The
second part deals with the antiviral agents currently in use or under clinical investiga-
tion. The third part contains a guideline for antiviral therapy.
Pathophysiology of virus disease
Virus structure: Viruses contain a single type ofnucleic acid, either ribonucleic acid
(RNA) or deoxyribonucleic acid (DNA). The viral core, composed ofthe nucleic acid
and nucleoproteins is protected by an outer protein coat (the capsid). In addition,
some viruses are surrounded by a lipoprotein envelope (Fig. 1).
Virus cell interactions: Viruses are obligate intracellular parasites. They do not
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FIG. 1. Schematic illustration of an enveloped icosahedral virus.
contain the genetic information for all the enzymes involved in viral replication and
they lack organelles required for energy generation and protein synthesis. The viral
replication cycle may be depicted as follows (Fig. 2): before a virus penetrates a cell, it
must come into close contact with, and attach itself to, the cell surface (step 1). This
step is often determined by highly specific cell receptors and viral surface properties.
Penetration into the cell (step 2) occurs through fusion ofthe viral lipid envelope with
the cytoplasmic membrane (Fig. 2), or by engulfment ofthe virus by the cell. Inside
the cell the viral protein mantle is removed (uncoated) (step 3), and the viral nucleic
acid is transported to the site of replication (step 4), which may be either the nucleus,
as shown in Fig. 2, or the cytoplasm, depending on the virus. Nucleic acid replication
(step 5) and transcription into messenger RNA (step 6) as well as viral protein
synthesis (step 7) are accomplished by cellular enzymes, and/or by specific enzymes
induced by the virus. Viral proteins are synthesized on ribosomes, and, together with
newly formed nucleic acid, are assembled into whole virus particles (step 8). These, in
turn, are released from the cell (step 9). The viral envelope is acquired by budding
through the nuclear or cytoplasmic cell membranes in which virus specific proteins
may have been incorporated.
During replication most viruses induce cytopathic effects, often leading to cell
death. Some viruses induce syncytia formation by altering the surface properties of
the cell. In addition, aggregation of viral components or alterations ofcell organelles
may result in characteristic inclusion bodies. The mechanism by which viruses induce
cytopathic effects [7] is often poorly understood. However, inhibition of essential
cellular metabolic reactions such as protein or nucleic acid synthesis may occur.
Cytopathic effects may be induced by viral parts or intermediate viral products
without involving a complete viral cycle.
Virus-host interactions: Virus infection occurs only if the virus is able to breach
barriers, such as skin or mucous membranes. Virus replication may be limited to the
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FIG. 2. Schematic illustration of the steps involved in the replication of an enveloped virus (see text).
barrier site, as, for example, in most viral respiratory infections (Fig. 3A). In virus
diseases with this pattern the interval between exposure to the virus and the clinical
appearance of viral damage (clinical symptoms)-the incubation period-will be
short. Symptoms will prevail at the site of viral replication, although host reactions
(see below) and viral and cellular toxic products can produce systemic symptoms.
Certain viruses (e.g., measles, rabies, etc.) not only replicate at the barrier site, but
spread to a secondary replication site by the blood stream, lymphatic, bronchial, or
neural routes (Fig. 3B). Viral replication at the barrier site in these diseases may be
asymptomatic and symptoms appear only when a secondary target organ isaffected:
the incubation period of these diseases is longer.
The symptomatology ofviral disease is not only due to virus-induced cell injury [8]
but is also influenced by the host response [9] (Fig. 4). Host reactions may be non-
specific, such -as inflammation, phagocytosis, interferon production and fever, or
specific, such as humoral and cellular immune responses. Often they restrict viral
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FIG. 3. Viral infection with short (A) and long (B) incubation period (I.P.) (see text).
damage, eliminate the virus, and prevent bothfurtherspread ofvirus and reinfection.
However, host responses may also be deleterious. Indeed, symptoms often appear
only when viral replication is already declining and must be attributed, at least in
part, to the host's "defense" mechanisms. For instance, inflammatory edema in
response to virus infection may not only be painful but have serious consequences
(e.g., in viral encephalitis). Virus-antibody complexes can lead to immune complex
disease (e.g., glomerulonephritis). Finally, cellular immune responses play a major
part in viral disease patterns. Indeed, the classical clinical presentations ofsome viral
diseases such as hepatitis, post-infectious encephalitis and exanthematous diseases
are mainly due to cellular immune responses; viral damage per se may be minimal.
This fact can be demonstrated in animal models in which immunosuppression may
prevent symptomatic disease in some viral infections [10]. It has also been suggested
that alterations of cell surface properties by viral replication, may initiate immune
reactions leading to autoimmune disease [11].
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FIG. 4. Host immune defense mechanisms to viral infection.
Recovery is usually associated with total elimination ofthe virus. However, some
viruses such as herpes viruses and "slow" viruses, may remain latent in certain tissues
after primary infection and become the source of (recurrent) disease after a latent
period.
General aspects ofantiviral therapy
Taking into account the above considerations about the pathophysiology ofviral
disease, the following points should be considered, whenever planning to apply
antiviral therapy.
Intracellularpenetration ofantiviral drugs: As viral replication occurs intracellu-
larly, an ideal antiviral drug should be able to penetrate the cell membrane. Drugs
whose action is limited to the extracellular space must be administered before the
virus reaches the cells of the target organs, that is, in most instances, early duringthe
incubation period.
Timing ofantiviral therapy: Even when using drugs which are able to penetrate the
cytoplasmic membrane, timing may be difficult. Indeed, ideal antiviral therapy
should be applied before viral replication has caused widespread, possibly irreversi-
ble, cytopathic effects. Moreover, when clinical symptoms occur, viral replication has
often reached its peak. At that time specific therapy may have little additional action
on its further decline. Unfortunately treatment with antiviral agents is usually
considered relatively late in the illness when non specific measures have failed or
when the clinical situation is desperate. In most situations the chances of success at
this stage are very small.
Specificity ofantiviral drugs: Until recently, toxicity has been a major problem in
the use of antiviral drugs. As viral replication is so closely related to and dependant
on cell metabolism, few antiviral drugs are really virus specific. The therapeutic
margin is small. Therefore, when planning antiviral therapy, beneficial actions of a
chosen drug have to be carefully balanced against possible toxic effects.
Spectrum ofantiviral drugs: An ideal antiviral drug should have a wide antiviral
spectrum, as it is often impossible to make an exact viral diagnosis on clinical or
laboratory grounds early during a viral disease, when antiviral therapy is most likely
to succeed. Due to their potential toxicity, antiviral drugs with a limited antiviral
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spectrum cannot be given, before an (often time consuming) etiological diagnosis has
been obtained.
Treating host or virus?.: Considering these difficulties, it is reasonable to continue
to treat most of the often harmless viral diseases by purely supportive measures, and
by using analgesics and anti-inflammatory drugs. These latter may be beneficial, as
host inflammatory reactions often aggravate the symptomatology of viral illnesses.
However, anti-inflammatory drugs, especially corticosteroids [12] and even some-
times salicylates [13], may actually favor viral replication by diminishing host defense
mechanisms. Therefore, unrestricted use of anti-inflammatory drugs should be
avoided.
In spite of these restrictions, a small number of antiviral drugs, described in the
following section, have been found useful in a number of well defined clinical
situations.
The different modes of antiviral therapy and the possible side effects are described
in Fig. 5.
ANTIVIRAL SUBSTANCES
Introduction
Many potential antiviral substances have been tested in tissue culture systems but
only a small number have reached the level ofanimal experiments and even fewer are
possibly useful in clinical practice. The main problem in achieving specific antiviral
therapy lies in the fact that viral multiplication is so closely associated with cellular
metabolism that most antiviral drugs also affect cell function. However, close exami-
nation of viral replication (Fig. 2) reveals a number of potential sites for selective
inhibition. Adsorption (step 1), penetration (step 2), and uncoating (step 3) are all
apparently unique to the virus. Little is known about step 4 (transport). Synthesis of
virus components (steps 5, 6 and 7) depend heavily on the use of cellular enzymes,
rendering selective inhibition often impossible. However, some viruses induce new
virus-specific enzymes and these may be selectively inhibited. Finally, there is some
evidence that assembly (step 8) and release (step 9) can be adversely affected. Table 1
summarizes the probable sites of action of some of the most commonly mentioned
antiviral agents. In this section the use ofimmunoglobulins, amantadine, nucleoside
analogs, methisazone and interferon will be described in detail. The other drugs
mentioned in Table 1 are either too toxic (HBB, guanidine, actinomycin D) or too
inactive (rifampicine) to be considered clinically useful, or have not yet undergone
enough clinical testing (phosphonoacetic acid, isoprinosine).
Immunoglobulins
General aspects: The use of immune serum globulin (ISG) in the treatment ofviral
disease has several advantages over other modes of antiviral therapy. ISG, acting as
"fneutralizing" antibody, is highly effective in the prevention of extracellular dissemi-
nation of virus. Furthermore, ISG does essentially not harm the host, imitating a
normally occurring host response. This therapeutic approach is especially useful in
patients in whom normal immune responses are not elicited. However, ISG has a
major disadvantage in that it does not pass the cytoplasmic membrane. Thus the
virus is only vulnerable during extracellular spread, which in most instances is during
hematogenous dissemination. Therefore, ISG has to be given before occurrence of
viremia and infection of the target organ. Thus, in most instances, the moment of
exposure must be known and ISG should be administered shortly thereafter. In fact,
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FIG. 5. Possible modes ofantiviral therapy: 1. active immunization (antiviral prophylaxis); 2. passive immunization by
immunoglobulins; 3. antiviral drugs; 4. antiinflammatory drugs.
treatment with ISG may be considered as an extension of antiviral prophylaxis
("postexposure prophylaxis"). It is also evident, that ISG postexposure prophylaxis
is usually ineffective in viral infections limited to the barrier site, such as respiratory
diseases.
Commercially available ISG contains primarily IgG antibodies at a protein con-
centration of 16 g/ 100 ml, an approximate fifteen-fold increase over the level of IgG
in plasma. These preparations are obtained from pooled plasma of random blood
donors. As such, they are representative of the general immunity of the donor
population (herd immunity) and of broad current disease trends. In these "standard"
ISG preparations, the level of specific antibody against a given viral disease is often
too lowfor adequate protection. Hyperimmune serum globulin (HISG) preparations,
obtained from patients recovering from or vaccinated against certain diseases,
contain a much higher content of specific antibodies, and are therefore often more
appropriate for postexposure immunization. The supply of these preparations is
limited and costs are high.
In general, ISG cannot be given intravenously because anaphylactic reaction may
occur, due to IgG aggregates formed during the fractionation procedures [14]. ISG,
given by the intramuscular route, reaches only about 40% of the maximal levels of
equivalent doses given intravenously and this peak is only attained after several days
[15]. This delay may be critical in the treatment ofviral disease. ISG prepared for the
intravenous route have in general either less immunologic properties or are excreted
much more rapidly than intramuscular preparations [14]. Recently developed plas-
min treated ISG does not seem to have these disadvantages [16]. However, HISG of
this type are not yet available.
Post-exposure immunization in viral disease:
a. Rabies: Rabies has such an exceptionally long incubation period that vaccine-
induced active immunity may be elicited even after exposure. Pasteur first made use
of this fact in 1882 when he actively immunized a patient bitten by a rabid dog [17].
However, subsequent attempts to prevent clinical disease by postexposure vaccina-
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TABLE I
Probable Action Sites of Some Antiviral Substances
Site of Drug Action Antiviral Substance
Attachment Immunoglobulins
Penetration Amantadine HCI
Uncoating Immunoglobulins
Nucleic acid RNA viruses 2 (alpha-hydroxybenzyl) Benzimidazole (HBB)
replication Guanidine
Photodynamic dyes
DNA viruses Nucleoside analogs
Photodynamic dyes
Phosphonoacetic acid
Protein syn- Transcription Actinomycin D
thesis Interferon
Translation Thiosemicarbazones (Marboran)
Interferon
Isoprinosine (?)
Assembly Rifampicin
tion have not been uniformly successful, especially when the incubation period was
short (e.g., when rabid bites were located in the head region [18]). In experimental
animal rabies (where the incubation period is shorter) immune serum has an addi-
tional protective effect, especially after a high virus challenge dose [19,20]. In man,
the beneficial effect ofpassive immunization (in addition to the vaccine) was demon-
strated after a devastating attack by a rabid wolf in Iran in 1953 [18]: addition of
rabies immune serum dramatically reduced the mortality in the patients bitten in the
head region. Later studies in the same country showed that mortality rates after
rabies exposure were reduced from about 20 percent to less than 1.5 percent by
postexposure treatment with rabies hyperimmune serum globulin [21]. Therefore,
both vaccine and serotherapy are clearly indicated, if there is heavy exposure to
rabies.
Unfortunately, the simultaneous administration of ISG with the vaccine interferes
with the stimulation of active immunity [22,23]. Therefore, the vaccine must be
applied repeatedly and for a prolonged period [24]. Furthermore, the Pasteur type
vaccines, derived from nervous tissue, may cause severe side effects [25]. Non-nervous
vaccines, especially duck embryo vaccine, are safer [26], but less immunogenic [27].
Vaccines produced in tissue cultures, e.g., human fibroblasts, elicit a high antibody
response, and are exempt from severe secondary reactions [28-30].
The occurrence of serum sickness in more than 40% of the adult recipients of
heterologous (horse) serum [31] can now be avoided by the use of human rabies
HISG, prepared from immunized volunteers [32,33].
b. Measles (rubeola): Standard ISG or rubeola HISG can prevent or attenuate
clinical measles if given within the first five (or more?) days after exposure [34,35].
Since the "incubation period" ofvaccine (attenuated) measles is shorter than that of
the natural disease it is possible to prevent the disease by active immunization during
the first 48 hours after exposure [36].
c. Rubella (German measles): Only about 15 percent of the adult population are
susceptible to rubella. Rubella causes malformations in 10 to 50% of the offspring of
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susceptible pregnant women who become infected during the first trimester. Since
rubella virus probably reaches the fetus by hematogenous and transplacental routes,
it is theoretically possible to prevent fetal infection bygiving ISG. Clinical manifesta-
tions of and seroconversion to rubella can be prevented by the use of high titered
rubella HISG [37] in volunteers. Unfortunately, controlled field trials [38], particu-
larly in pregnant women exposed to rubella [39], have failed to show evidence of
protection by rubella HISG. These failures may be due to the fact that rubella HISG
is rarely given early enough after exposure. The exact time of exposure is difficult to
ascertain as an infected person sheds virus one week before and up to two weeks after
the appearance of the rash [40].
d. Varicella-zoster: Chickenpox, usually a mild childhood disease, may be a serious
threat to patients with congenital, acquired or drug induced immune deficiencies.
Recurrent varicella-zoster virus infection in the form of shingles (herpes zoster) may
also be severe and generalized in immunosuppressed patients. Standard ISG in high
doses may attenuate but not prevent chickenpox in a normal population [41]. High
titered zoster HISG (prepared from patients recovering from herpes zoster) can
prevent varicella in normal children [42] and is likely to attenuate the disease in
immunosuppressed patients [43-45]. There is no evidence that zoster HISG is ofany
effect once the rash has appeared [46].
e. Mumps (epidemicparotitis): Although the incubation period of mumps is more
than two weeks, administration of HISG after exposure is not always successful in
preventing the illness [47]. Some [48-51], but not all [52], controlled trials indicate
that the incidence of mumps orchitis, but not that of encephalitis [49], may be
decreased by administration of high dose mumps HISG, even after parotitis has
appeared.
f. Smallpox (variola) and smallpox vaccination complication (vaccinia): After
smallpox contact, the disease may be prevented or attenuated by vaccinia HISG
[53,54]. The effect of simultaneous (re)vaccination is doubtful, but it is indicated as a
public health measure [53]. Once the rash has appeared, immunotherapy is unlikely
to be effective [53]. There are only uncontrolled data to show the value of vaccinia
HISG in the treatment ofvaccinia complications. No effect has been demonstrated in
the treatment of post-vaccinial encephalitis [55]. Eczema vaccinatum and ocular
inoculation vaccinia are generally regarded as indications for the use ofhyperimmune
globulin [53,55,56]. Vaccinia gangrenosa is a frequently lethal complication of
vaccination occurring in patients with impaired immunity [57]. Vaccinia HISGalone,
although indicated, is rarely effective [55].
g. Hepatitis A and B: The data about the efficacy ofimmunoglobulins in postexpo-
sure immunization of viral hepatitis are conflicting. This confusion is in part due to
the facts that in the older literature anicteric hepatitis was not detected, hepatitis A
and B could not be differentiated, and the content ofspecific hepatitis B antibody in
the preparations, which may vary from one batch to another [58], was not known. At
present, it is well established that non-parenterally transmitted hepatitis A may be
prevented by low dose standard ISG [59-63]. Passive immunization may be effective
as long as one to two weeks after exposure [62]. Standard ISG is probably not
effective in the prevention ofhepatitis B unless it contains some antibodyagainst this
virus [64-66]. Hepatitis B HISG may have a favorable prophylacticeffect in people at
high risk of acquiring hepatitis B [67-71]. However, protection is neither complete
nor uniform. In one study of medical workers accidentally (by needle puncture)
exposed to hepatitis B, it was found that the disease could be delayed but not
prevented [72]. Clearly much more information is needed before recommendations
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can be given about the clinical effects, indications, dosage, possible time interval after
exposure, etc., of hepatitis B HISG.
The occurrence of transfusion transmitted hepatitis B has been greatly reduced by
screening of donor blood for hepatitis B-antigen (HBsAg). In spite of this, post-
transfusion hepatitis still occurs. It is probably due neither to hepatitis A nor B virus
[73,74]. In a preliminary study the incidence of non A, non B hepatitis was reduced
by administration of ISG during transfusion [75].
Synthetic antiviral drugs
Amantadine: Amantadine (I-Adamantanamine hydrochloride) (Fig. 6A) inhibits
the replication ofcertain strains of influenza A and C viruses and some paramyxovi-
ruses [76,77]. In high doses it protects tissue cultures from rubella and respiratory
syncytial viruses, but it has no effect on influenza B [77].
Amantadine prevents virus penetration through the cytoplasmic membrane by an
unknown mechanism [76]. In therapeutic doses it has no effect on virus or host cell
DNA, or on protein synthesis [76]. In tissue culture, the drug is inactive when
administered as short as five minutes after infection [76]. However, mice are pro-
tected if the drug is given even 48 hours after challenge [78]. Drug resistance can be
induced in vitro [77].
In man, amantadine has been shown to be effective in the prophylaxis ofinfluenza
A. In experimental [79-81] as well as in epidemic field studies [82,83], the incidence
of infection, the severity and duration of symptoms and the duration of virus
shedding were significantly reduced by the drug. Some reports [84-87], but not all
[79,88] have also demonstrated some therapeutic activity of amantadine when given
shortly after apparition of symptoms. In most trials no side effects have been
observed [80,83,85,86]. However, central nervous system symptoms, such as dizzi-
ness, nervousness, insomnia or even hallucinations may occur [82].
Rimantadine (a-methyl-l-adamantanemethylamine hydrochloride) a close
analog of amantadine has been shown to be more effective against influenza A
infection in tissue culture and animals [89,90]. There is less tendency for virus
resistance to occur with rimantadine than with amantadine. Amantadine resistant
viruses remain sensitive to rimantadine but the converse is not true [90]. In man,
rimantadine is at least equally active as amantadine [86,91].
Nucleoside analogs: Nucleoside analogs act on purine and pyrimidine metabolism
either by competitive inhibition or by incorporation as "false" subunits into nucleic
acids. As a result, nucleic acid synthesis may be altered as well as metabolism of
protein and carbohydrates [92].
Theoretically, a nucleoside analog may have a selective antiviral effect if one oftwo
conditions are fulfilled: 1. The agent may be modified by virus induced enzymes into
an active compound. This will result in a higher concentration of the inhibitory
principle in infected cells. 2. The virus may code for an enzyme which is more easily
inhibited by the drug than the corresponding enzyme of the host cell [93].
a. 5-iodo-2'-deoxyuridine (IDU) (Fig. 6B): The thymidine analog IDU was the first
antiviral drug to be used successfully in man by Kaufman et al. in 1962 [94] and has
since become standard treatment for herpes simplex keratitis.
Its antiviral action is complex. IDU is a competitive inhibitor ofthymidine kinase.
Furthermore, it is incorporated into DNA [95]. Thymidine kinase activity although
sometimes enhanced by viral multiplication [96] is an important cellular enzyme.
Thus, a dose sufficient to arrest viral multiplication is likely to impede cell metabo-
lism as well. In other words, the therapeutic margin is narrow.
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FIG. 6. Synthetic antiviral drugs: (a) I-Adamantanamine hydrochloride (Amantadine); (b) Nucleosideanalogs (X
CH3: thymidine; X = H: 2-deoxyuridine; X = I: 5-iodo-2'-deoxyuridine (IDU); (c) I-(3-D-arabinofuranosyl-cytosine(ara-
C); (d) 9- -D-arabinofuranosyl-adenine (ara-A); (e) 9-f-D-arabinofuranosyl-hypoxanthine(ara-Hx); (f) N-methylisatinj3-
thiosemicarbazone (Marboran).
IDU is effective in vitro against most DNA viruses. However, in vitro resistance is
readily observed and is due to viral mutants which fail to induce thymidine kinase
[97]. IDU is active in animals infected by herpes simplex, particularly as a topical
agent in keratitis [98]. IDU does not easily pass the "blood-brain barrier" [99,100]
and is rapidly metabolized to inactive compounds [101]. Therefore, little effect can be
demonstrated on experimental herpes simplex encephalitis [99,102,103].
In man, success rates oftopical IDU in the treatment ofsuperficial herpes simplex
keratitis vary from 68 to 85% [104-106]. IDU is not active in the deeper (stromal)
keratitis. Furthermore, resistance to the drug has been observed [94].
There is no convincing evidence that IDU is effective in recurrent cutaneous herpes
simplex. Whether IDU treatment is more effective (and safe) after addition of
dimethylsulfoxide (DMSO) [107] remains to be confirmed. Multiple case reports and
small uncontrolled series have suggested a favorable action ofIDU in herpes simplex
encephalitis. The only prospective study to date had to be interrupted because of
unacceptable toxicity [108].
Systemically administered, IDU may have, at least theoretically, not only immedi-
ate, but also long lasting serious side effects. It is incorporated into DNA and may
therefore induce mutations 1109]. Furthermore, IDU has been shown in vitro to
activate "dormant" tumor viruses [110]. Thus, the use of IDU should be restricted to
topical ophthalmic treatment.
b. Cytosinearabinoside (1-/3 -D-arabinofuranosyl-cytosine, ara-C) (Fig. 6C): Ara-
C blocks DNA synthesis, partly by inhibiting DNA polymerase [111] and partly by
competing with the phosphorylation of deoxycytidine [112]. Ara-C is incorporated
into DNA but does not depend on this for its antiviral action [111]. In experimental
in vitro and animal studies, the drugis effective against DNA viruses [113]. However,
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cellular DNA synthesis is also impeded [113,114]. Furthermore, ara-C exhibits local
toxicity when used in experimental herpetic keratitis [115].
In man, the drug is rapidly deaminated to an inactive compound (1-,3 -D-
arabinofuranosyl-uracil (ara-U) [116,117], and must therefore be given by continuous
intravenous infusion. Clinically, the drug has been used in herpes virus infection,
mainly in uncontrolled studies. The few placebo controlled prospective double blind
studies in disseminated [118,119] or localized [120] zoster infections in immunosup-
pressed hosts and in variola [121], showed that toxicity was greater than the benefi-
cial action. Although active on herpetic keratitis (and particularly on IDU resistant
strains of herpes simplex) its effect is hampered by the appearance of glittering
corneal deposits [115,122]. Ara-C has probably no further clinical use as an antiviral
agent.
c. Adenine arabinoside (9-,8-D-arabinofuranosyl-adenine (ara-A) (Fig. 6D): Ara-
A is a potent antiviral agent against DNA viruses (with the exception of adenovi-
ruses) [123,124]. Its mode of action is not completely understood, but includes
inhibition of DNA polymerase [125]. Small amounts of ara-A are incorporated into
DNA [126]. Tissue culture and animal experiments with ara-A have demonstrated a
much higher therapeutic margin than with ara-C and IDU [124]. Resistance is rarely
observed. Furthermore, ara-A is active against IDU resistant herpes simplex strains
[127]. The effect on experimental herpetic keratitis is similar to that ofIDU [128]. In
animal studies, herpes simplex encephalitis reacts favorably to ara-A [123,128],
probably because ara-A or its metabolites (see below) easily pass the "blood-brain
barrier" [129,130].
Like other nucleoside analogs, ara-A is rapidly metabolized. However, the main
metabolite, 9-1 -D-arabinofuranosyl-hypoxanthine (ara-Hx) (Fig. 6E), also has some
antiviral activity, and no major toxicity to host cells [130]. Blockage ofdeamination
of ara-A to ara-Hx enhances the activity of ara-A [131].
Ara-A is not well absorbed ifgiven per os and must therefore be given parenterally.
In man, where the drug is also rapidly metabolized to ara-Hx, about 50%ofara-Hx is
excreted in the urine [130]. In serum, urine, CSF, and vitreous humor, antiviral
activity is almost exclusively due to ara-Hx [130]. The serum half life of ara-Hx is
about 3.5 hours. CSF levels may reach about half of the serum levels [130].
At present, only a few controlled trials with ara-A are available. Herpes simplex
keratitis responds to ara-A at least as well as to IDU [132]. Its activity on IDU
resistant keratitis, and the beneficial influence on herpetic kerato-uveitis [133] when
used parenterally are real advantages ofara-A over IDU. Recently, it has been shown
that ara-A has a beneficial effect on the evolution of systemic herpes zoster in
immunosuppressed patients [134].1 Preliminary uncontrolled experiments suggest a
favorable action in severe mucocutaneous herpes simplex infections [135] and in
neonatal disseminated herpes simplex [136]. In most trials, few side effects were
observed. However, when used in high dosage (20 mg/kg for several days) nausea,
tremor and hematologic abnormalities may be observed [137]. Ara-A does not
influence established smallpox infection [138] and is ineffective for cutaneous herpes
simplex when used topically [139]. It has little or no effect on established cytomega-
lovirus infection [140,141].
At present, ara-A is the nucleoside analog with great promise of clinical efficacy.
'Ara-A, if given early, has very recently been shown to diminish significantly mortality and sequellae in noncomatose
patients with biopsy-proved herpes simplex encephalitis (Whitley RJ, Soong S-J, Dolin R, et al: Adenine arabinoside
therapy of biopsy-proved herpes simplex encephalitis. N Eng J Med 297:289, 1977).
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d. Other nucleoside analogs: It is likely that in the near future, other nucleoside
analogs will be introduced. Several have already reached the level of clinical trials
(e.g., trifluorothymidine in herpetic keratitis [142], ribavirin (virazole) which has a
large antiviral spectrum [143], etc.). It is beyond this review to discuss these sub-
stances. For references see reference 92.
Thiosemicarbazones (Methisazone): In 1950, Hamre et al. [144] opened the era of
antiviral therapy by demonstrating that a thiosemicarbazone derivative protects the
chick embryo and mice from otherwise fatal vaccinia virus infection. Thiosemicarba-
zones, especially those substituted with an aromatic ring such as isatin (Fig. 6F)
interfere with the multiplication of poxviruses and, at least in vitro, some other DNA
and RNA viruses [145,146]. They act on "late" messenger RNA translation in
polyribosomes without inhibiting host cell functions [147-149]. However, even
though virus particles cannot be fully assembled, cytopathic effect by the virus is not
prevented [147].
Reports of the efficacy ofthiosemicarbazones in man are conflicting. Methisazone
(5-methylisatin thiosemicarbazone, Fig. 6F) is the derivative which has been the most
thoroughly studied. Early enthusiasm for methisazone in the treatment of smallpox
during the incubation period [150,151] has been challenged by the results ofplacebo-
controlled double-blind studies [152,153]. It is likely that the drug has some effect
shortly after exposure, but is ineffective once the rash has appeared [154]. No
controlled data are available on thiosemicarbazones in vaccinia gangrenosa or
eczema vaccinatum [155,156].
Besides nausea and vomiting, which occur frequently, methisazone has no side
effects [150,151].
Photodynamic dyes: Some antiviral drugs ("photodynamic dyes") exhibit their
action only following interaction with light [157]. These compounds bind to the
guanine bases of nucleic acids. Activated by ultraviolet light, they lead to the
oxygenation of the base and consequently to a breakage of the nucleic acid [158]. In
vitro, several RNA and DNAviruses, and particularly herpes simplex virus [159], are
inactivated if treated with a photodynamic dye such as proflavin or neutral red, and
subsequently exposed to ultraviolet or visible light. Experimental rabbit herpes
simplex virus keratitis [160], has been successfully treated with photodynamic dyes,
although the effect was inferior to the well established IDU treatment [161].
The use of photodynamic dyes in man remains controversial: 1. They are not
selectively virucidal, but also destroy tissue culture cells [157]. 2. Experiments with
hamster fibroblasts have shown that herpes simplex viruses, when inactivated by
neutral red and light, may reveal theircapacity to render cells malignant (transforma-
tion) [162]. Although this mechanism has never been demonstrated in vivo, too short
a time has elapsed -since the application of photodynamic dyes in the treatment of
human herpes simplex skin lesions to exclude this potentially disastrous side effect. 3.
Earlier published favorable results of the treatment of herpes simplex skin lesions by
photodynamic dyes [163] have recently been challenged by carefully controlled
studies [164,165].
Other approaches to antiviral therapy: interferon and interferon inducers
Interferon(s) (IF), discovered by Isaacs and Lindenmann in 1957 [166], is a
naturally occurring glycoprotein with potent antiviral activity [167,168]. Human IF,
although not homogenous, has a molecular weight ofapproximately 20.000 daltons
[169]. IF formation (and release) is induced by viral infection. Furthermore, proto-
zoal or bacterial products (e.g., endotoxin), double stranded RNA and synthetic
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compounds may act as IF inducers [170]. IF has no direct action on viruses and does
not inhibit adsorption, penetration, uncoating or release. It appears to act by
inducing an antiviral protein within the cell which subsequently inhibits viral RNA or
protein synthesis [171-173]. With some exceptions [174] IF is species or at least order
specific, depending probably on specific IF receptors on the host cell membrane
[175]. Its antiviral spectrum includes both RNA and DNA viruses. Some viruses, e.g.,
adeno- and herpesviruses, may be more resistant than others [176]. Although any cell
may produce IF, lymphocytes appear to be a major source of IF. After immune
stimulation, IF is released in conjunction with other lymphokines [177]. There are
several facts which suggest that IF plays an important role in the recovery of viral
disease: 1. Recovery is often associated with the early appearance of IF but not
necessarily with inflammation or humoral immune responses [178,179]. 2. Immune
suppressed patients in whom certain viral diseases are more serious, have delayed IF
responses to viral infection [179,180]. Furthermore, animals treated with specific
antibody to IF are highly susceptible to viral infection [181]. 3. Application of IF or
IF inducers may inhibit viral damage and accelerate recovery not only in tissue
culture but also in animals and in man (see below) [167,168]. Although IF has been
considered non toxic, it has recently been found that it may inhibit DNA synthesis
[182] and cell division [183,184]. Cellular [185,186] and humoral [187] immune
responses may also be inhibited by IF. Furthermore, IF in high titers is toxic to
newborn mice [188]. As IF is species specific and potentially antigenic, it has to be
produced from human cells. The main source has so far been human leukocytes, but
tissue culture cells may be another more easily available source [189]. After paren-
teral injection of IF, levels which are known to be antiviral in vitro, are reached in
blood [190,191]. There is only irregular passage in urine and none into cerebrospinal
fluid [190,191]. Serum half life is between 1½2 and almost 5 hours after equal
distribution has occurred. Some cumulation may be observed if IF is given repeatedly
[190]. The few side effects observed (e.g., fever, and slight depression of the bone
marrow [192] have not been serious.
There have been few clinical trials which allow assessment of the efficacy of human
IF [193]. Respiratory infections can be prevented by intranasal IF [194,195]. IF,
administered parenterally over a long period reduces the amount of hepatitis B-DNA
polymerase found in serum; this, however, may not be a direct effect of IF [192].
Prospective studies in severe varicella-zoster infection are being conducted [193]. So
far, the results of topical human IF in herpetic keratitis are rather disappointing
[196]. Because of the difficulties of producing IF in high concentrations much work
has been done using synthetic IF inducers [170]. Unfortunately, stimulation of IF by
inducers becomes often refractory after repeated doses. Inducers which have been
used in man include: synthetic polymerized double-standard RNA!s such as polyribo-
inosinic acid-polyribocytidylic acid (poly IR-POIY CR) [197] and substituted pro-
panediamines [198-200]. The available data from man do not establish that the
antiviral action of these substances is due to IF induction. Furthermore, some of
these substances are considerably toxic.
In summary, although indications are not yet established, IF and IF inducers may
become clinically useful. Like immunoglobulin, IF is a natural product with a broad
antiviral spectrum and low toxicity. The use of potent and non toxic IF inducers
would circumvent the difficulties and the cost of the production of IF from human
cells.
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How many patients, especially in hospital, are allowed to recover from their viral infection without antibiotics? [201]
It is hoped that this section may serve as a guideline for specific antiviral treatment.
Diseases for which no specific treatment is available (e.g., viral meningitis) will not be
mentioned below. Furthermore, it is not within the scope of this review to describe
merely supportive, albeit important measures (such as rehabilitation in poliomyelitis).
Hepatitis A and B: The following persons should receive low dose standard ISG
(0.02 ml/kg i.m.) [202]: family members in contact with a case of overt hepatitis A,
persons accidentally pricked by needles contaminated with blood from patients
suffering from hepatitis A, personnel working and patients hospitalized in institu-
tions where hepatitis A is endemic, persons exposed to a common source outbreak of
hepatitis A and finally people travelling in endemic (tropical) areas. The dose may be
doubled and repeated after 4-6 months, if the exposure is prolonged. For the
moment, guidelines for indications and dosages of hepatitis B HISG are not yet fully
established. The following persons may benefit from HISG: newborn infants of
hepatitis B-antigen positive mothers [67], family contacts exposed to hepatitis B [70],
medical personnel accidentally exposed to hepatitis B [70], and both patients and
personnel in dialysis and oncology units [68,71]. If standard ISG is used, it should
contain specific anti-hepatitis B antibody.
Herpes simplex: Reports of treatment of herpetic skin lesions should always be
compared with the high "success rate" of placebo treatment which may reach more
than 70% [203,204]. Indeed, there is no proof that any specific antiviral treatment
(e.g., nucleoside analogs, photodynamic dyes, etc.) is of more value than simple
disinfection. Furthermore, there is little hope that the recurrence of herpetic skin
lesions may be influenced by any topical treatment because the "reservoir" of herpes
simplex virus is likely to be situated in the sensory ganglia (trigeminal or sacral).
In the past, vaccination by vaccinia or inactivated herpes simplex virus has been
proposed. In small, but controlled studies both these treatments have been shown to
be ineffective [203,204]. Vaccination with inactivated herpes simplex should be
abandoned for two other reasons: 1. there is no definite proof of an immune defect in
persons prone to recurrent herpetic skin lesions and therefore, no strong argument
for vaccination; 2. introduction of viral genetic material may be potentially hazar-
dous due to the known oncogenic properties of herpes viruses.
Active genital herpes at the time of delivery exposes the newborn to a high risk of
infection [205,206]. In these cases in which there are active lesions and on condition
that the membranes have been ruptured for less than four to six hours, cesarian
section has been recommended [205,206]. Preliminary reports indicate that ara-A
may be effective if given early in established neonatal infection [136].
Skin and mucous lesions may become chronic and very painful in immunosup-
pressed patients. Preliminary studies show that parenteral use of ara-A may be
helpful [135]. There have been many reports of successful treatment of herpes
simplex encephalitis. These should be interpreted with caution because in many cases
the etiology of encephalitis has not been firmly established and the spontaneous
evolution of this disease is unpredictable [207]. IDU should be abandoned in this
disease [108]. At present there are no reports adequate forjudging the efficacy ofara-
A in treating herpes encephalitis (see footnote 1).
If ara-A is given parenterally, the recommended doses are between 10 and 20
mg/kg/day for 5 to 10 days, given in a continuous infusion. At the higher doses,
521HANS STALDER
side effects include nausea, vomiting, tremor and bone marrow toxicity [137]. LFor
the treatment of ocular infections, the reader is referred to references 208 and 209.]
Influenza and other respiratory diseases: It is particularly disappointing that no
established antiviral treatment exists for one ofthe most common human syndromes,
viral respiratory illness. Amantadine (or its close derivate rimantadine) is effective in
the prophylaxis of some influenza A infections [79-83,86,91] and may alter the
disease course if given almost immediately after appearance of symptoms [84,85,87].
No effect has been demonstrated in other respiratory infections ofman. This selectiv-
ity, in addition to the difficulty of making an exact viral diagnosis early during a
respiratory illness, and the necessity to give the drug immediately, limit the use of
amantadine in medical practice. Furthermore, amantadine in the doses used (100 mg
p.o. twice daily for ten days) is not always exempt of side effects such as dizziness,
nervousness, insomnia or even confusion [82,210]. The drug is not metabolized. It is
entirely excreted by the kidney and the dosage should be reduced in renal failure
[211].
The topical use of interferon (and interferon inducers) is still experimental.
Measles (rubeola): Measles can (and should) be prevented by vaccine. There is
some evidence that active immunization may prevent measles up to 48 hours after
exposure [36]. During the first five days after exposure, passive protection using 0.2
ml/kg standard ISG intramuscularly should be given to all persons who have no
immunity to measles (negative history of either immunization or natural disease)
[212]. ISG or HISG are not effective in the treatment of encephalitis [213].
Mumps: Mumps live-attenuated vaccine provides a lasting immunity, but is not yet
widely used. Mumps HISG may diminish the incidence of orchitis in postpuberty
males even after appearance ofparotitis [48-51]. Its use remains controversial [214].
Contrary to common belief, mumps orchitis never leads to impotency and only rarely
to sterility [215]. In two prospective studies, it has been shown that steroids are no
more effective in the management of mumps orchitis than simple analgesics
[216,217].
Rabies: The prophylaxis of clinical rabies [218,219] after exposure is threefold: 1.
wound care; 2. active and 3. passive immunization. The first aim is to reduce local
load. The wound should be thoroughly rinsed with water, soap or alcohol immedi-
ately after exposure followed by a 1% quaternary ammonium base (after having
carefully removed all traces of soap). These latter compounds have been shown to be
virucidal in vitro and may, in addition, inhibit neural spread of the virus [220]. In
cases of heavy exposure, rabies immune serum or HISG (see below) should be
injected into and around the wound site. The wound should be left open. Simultane-
ously, duck embryo vaccine or, if available, human fibroblast derived vaccine [30]
should be administered. Fourteen daily doses of the former vaccine are recom-
mended. If serum or HISG is applied 21 doses should be given as either one dose
daily for 21 days, or two doses daily for seven days followed by seven daily doses.
Two booster doses after 10, 20 and 90 days respectively are necessary for a lasting
protection (fewer doses are needed for human fibroblast derived vaccine). In heavy
exposures, horse rabies hyperimmune serum (40 UI/kg, half of the dose into the
wound site and half i.m.) or preferentially human rabies HISG (20 UI/kg) should be
given. The indications of rabies prophylaxis are listed in Table 2.
Rubella (german measles): Rubella in children and nonpregnant adults is a
harmless disease which does not need specific treatment. For reasons discussed
earlier, postexposure immunization for pregnant women exposed to rubella is rarely
effective. If it is attempted, it should be noted that the absence ofclinical illness is not
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TABLE 2
Guide for Postexposure Rabies Prophylaxis in Endemic Areas [218,219].
Nature of Exposure Animal and Its Condition Treatment
No lesion, indirect Rabid None
contact, licks on
unabraded skin
Licks on abraded Domestic, healthy None'
skin or mucous
membranes. Scratches,
abrasions and
minor bites Rabid, suspect2 but Vaccine3
escaped, unknown
Deep or multiple Rabid or suspect Serum and vaccine3
bites, bites in
head region
Hold animal for ten days. If any signs ofdisease, the animal should be killed, and the brain examined forevidence of
rabies. If positive start vaccine.
2 Carnivorous animals and bats are more likely to be infective than other animals. An unprovoked attack is more
suspect than a provoked attack (e.g., attempts to feed).
3 In case of domestic or captured animals, stop treatment if the animal remains healthy after five days or if brain
examination of the killed animal is negative for rabies.
an index ofsuccessful prophylaxis: most ofadult rubella infections are asymptomatic
[221] but may still result in the fetopathy. Therefore, serum antibody titers against
rubella have to be assessed before and after passive immunization. A significant titer
rise means active infection with the known high risk to the fetus.
Smallpox: A person exposed to smallpox but not (re-)vaccinated during the past
three years should receive human vaccinia HISG (0.1 ml/kg) [53,54]. The indication
for methisazone given during the incubation period is controversial [150-153]. Once
the rash has appeared, the treatment of smallpox is purely supportive. Antiviral
drugs are ineffective [154,137].
Complications ofsmallpox vaccination (vaccinia): There are five major complica-
tions of smallpox vaccination: postvaccinial encephalitis, generalized vaccinia, ec-
zema vaccinatum, vaccinia gangrenosa and inoculation vaccinia [56]. All, except
encephalitis, can usually be prevented by strictly following the instructions for
smallpox vaccination.
There is no specific treatment for vaccinia encephalitis. Generalized vaccinia, due
to hematogenous spread of vaccinia virus, is not a serious condition and does not
need specific antiviral treatment. Patients sufferingfrom eczema who are accidentally
vaccinated or inoculated by a close contact should receive vaccinia HISG (0.6 ml/kg
i.m.) [53,55,56,222] (it should be given prophylactically in all patients with a history
of eczema, who need vaccination). Ifthere is no amelioration after repeated doses of
HISG, methisazone may be tried (200 mg/kg as a loading dose, then 400 mg/kg p.o.
in divided doses every 12 hours over the next two days [155,156]). Methisazone is not
toxic, but nausea and vomiting occur frequently. Vaccinia gangrenosa is a life-
threatening complication of smallpox vaccination in patients with deficient immu-
nity. Vaccinia HISG (0.6 ml/kg i.m.) is not sufficient therapy in most cases. Methisa-
zone (same doses as above) may be tried [155,156]. The transfusion oflymphocytes
from a recently vaccinated donor may also be effective [55,223]. The application of
vaccinia HISG [56] and topical IDU [224] has been advocated in patients inoculated
accidentally in the eye.
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No controlled data concerning ara-A therapy in vaccinia are available.
Varicella-zoster: Chickenpox is usually a mild childhood disease which requires no
treatment. In adults, varicella may be more severe, but the prognosis is good ifthere
is no underlying disease. Therefore, in these situations, the treatment should remain
supportive. However, in newborns and immunosuppressed patients, varicella (and
generalized zoster) may constitute a serious, even life-threatening, disease.
When available, zoster HISG (5 ml i.m.) (or plasma) obtained from patients
recovering from herpes zoster, should be given, whenever an immunosuppressed
child (without a history of varicella) is exposed to a patient with varicella or zoster
[225]. Newborns, whose mother contacted varicella within four days before delivery,
may also be protected by zoster HISG. There is no evidence that zoster HISG has any
beneficial action once the rash has appeared.
Ara-A, using the same dose as for HSV infections, is the only antiviral drug which
may be of use in varicella and generalized zoster in altered hosts [134]. Ara-C should
no longer be used since it is ineffective and toxic [118,119]. Interferon has beentried,
but definitive conclusion about efficacy cannot yet be drawn [192].
Uncomplicated herpes zoster does not need specific treatment. Preliminary results
of treatment with IDU in DMSO [226] need confirmation. Postherpetic pain may be
a major problem, especially in patients over 60 years. The use of corticosteroids in
this age group remains controversial. Although patients under longterm corticother-
apy suffering from varicella and zoster have often a prolonged and serious course,
there is no evidence that a short corticotherapy after appearance of the rash aggra-
vates the disease. Corticosteroids had a beneficial effect on zoster pain [227,228] but
there is no proof that other inflammatory drugs are not equally effective. Corticoster-
oids may therefore be tried, if the usual analgesics fail.
SUMMARY
Table 3 summarizes clinical use ofantiviral therapy. Positive statements "+" should
be interpreted in the sense that the drug may be indicated in some, but certainly not
all patients. The reader should refer to the appropriate sections of the text. Viral
illnesses in which there is no available treatment (such as enterovirus infection) or in
which antiviral therapy is still at an early experimental stage have been omitted.
ACKNOWLEDGMENTS
The help of Dr G. Friedli, Miss F. Michaud, Miss M.R. Payne, Drs M.J. Levin, M.N. Oxman, D.H. Smith, F.A.
Waldvogel and Mr M.A. Rychner was indispensable for the accomplishment ofthis review and is kindly acknowledged.
This work was partly supported by a fellowship from the Swiss Academy of Medical Sciences.
REFERENCES
1. Bauer DJ: Antiviral chemotherapy: the first decade. Br Med J 3: 275, 1973
2. Becker Y: Trends in research and development of antiviral substances. Isr J Med Sci 11: 1135, 1975
3. Hirschman SZ: Approaches to antiviral chemotherapy. Amer J Med 51: 699, 1971
4. Luby JP, Johnson MT, Jones SR: Antiviral chemotherapy. Annu Rev Med 25: 251, 1974
5. Weinstein L, Chang TW: The chemotherapy of viral infections. N Engl J Med 289: 725, 1973
6. Tilles JG: Antiviral agents. Annu Rev Pharmacol 14: 469, 1974
7. Bablanian R: Mechanisms of virus cytopathic effects. Symp Soc Gen Microbiol 22: 359, 1972
8. Smith H: Mechanisms of virus pathogenicity. Bacteriol Rev 36: 291, 1972
9. Webb HE, Hall JG: An assessment ofthe role ofthe allergic response in the pathogenesis ofviral diseases. Symp Soc
Gen Microbiol 22: 383, 1972
10. Hirsch MS, Murphy FA: Effects of anti-lymphoid sera on viral infections. Lancet 2: 37, 1968
11. Notkins AL, Mergenhagen SE, Howard RJ: Effect of virus infections on the function ofthe immune system. Annu
Rev Microbiol 24: 525, 1970
12. Dale DC, Petersdorf RG: Corticosteroids and infectious diseases. Med. Clin North Am 57: 1277, 1973526 HANS STALDER
13. Stanley ED, Jackson GG, Panusarn C, et al: Increased virus sheddingwith aspirin treatment ofrhinovirus infection.
JAMA 231: 1248, 1975
14. Barandun S, Skvaril F, Morell A: Prophylaxis and treatment of diseases by means of immunoglobulins. Monogr
Allergy 9: 39, 1975
15. Smith GN, Griffiths B, Mollison D, et al: Uptake of IgG after intramuscular and subcutaneous injection. Lancet 1:
1208, 1972
16. Barandun S, Castel V, Makula MF, et al: Clinical tolerance and catabolism of plasmin-treated -y-globulin for
intravenous application. Vox Sang 28: 157, 1975
17. Pasteur L: Methode pour prevenir la rage apres morsure. CR Acad Sci 101: 765, 1885
18. Baltazard M, Bahmanyar M, Ghodssi M, et al: Essai pratique du serum antirabique chez les mordus par loups
enrages. Bull WHO 13: 747, 1955
19. Koprowski H, Van den Scheer J, Black J: Use of hyperimmune antirabies serum concentrates in experimental
rabies. Am J Med 8: 412, 1950
20. Veeraghavan N, Subrahmanyan TP: Value ofantirabies vaccine with and without serum against severe challenges.
Bull WHO 22: 381, 1960
21. Bahmanyar M: Success and failure of sero-vaccination as prophylactic treatment of individuals exposed to rabies.
Symp Series immunobiol vol 1, pp 307-312. Basel: Karger, 1966
22. Wiktor TJ, Lerner RA, Koprowski H: Inhibitory effect of passive antibody on active immunity induced against
rabies by vaccination. Bull WHO 45: 747, 1971
23. Corey L, Hattwick MAW, Baer GM, et al: Serum neutralizing antibody after rabies postexposure prophylaxis.
Annals Int Med 85: 170, 1976
24. Atanasiu P, Dean DJ, Habel K, et al: Rabies neutralizing antibody response to different schedules of serum and
vaccine inoculation in non-exposed persons. Part 4. Bull WHO 36: 361, 1967
25. Turner GS: Rabies vaccines. Br Med Bull 25: 136, 1969
26. Rubin RH, Hattwick MAW, Jones S, et al: Adverse reactions to duck embryo rabies vaccine. Range and incidence.
Ann Intern Med 78: 643, 1973
27. Ellenbogen C, Slugg P: Rabies neutralizing antibody: inadequate response to equine antiserum and duck-embryo
vaccine. J Infect Dis 127: 433, 1973
28. Wiktor TJ, Plotkin SA, Grella DW: Human cell culture rabies vaccine: antibody response in man. JAMA 224:1170,
1973
29. Plotkin SA, Wiktor TJ, Koprowski H, et al: Immunization schedules forthe new human diploid cell vaccine against
rabies. Am J Epidemiol 103: 75, 1976
30. Bahmanyar M, Fayaz A, Nour-Salehi S, et al: Successful protection of humans exposed to rabies infection.
Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 236: 2751, 1976
31. Karliner JS, Belaval GS: Incidence of reactions following administration of antirabies serum: study of 526 cases.
JAMA 193: 359, 1965
32. Sikes RK: Human rabies immune globulin. Public Health Reports 84: 797, 1969
33. Cabasso VJ, Loofbourow JC, Roby RE, et al: Rabies immune globulin of human origin: preparation and dosage
determination in non-exposed volunteer subjects. Bull WHO 45: 303, 1971
34. Stokes J Jr, Maris EP, Gellis SS: Chemical, clinical, and immunological studies on the products of human plasma
fractionation. XI. The use ofconcentrated normal human serum gammaglobulin (human immune serumglobulin) in
the prophylaxis and treatment of measles. J Clin Invest 23: 531, 1944
35. Ordman CW, Jennings CG, Janeway CA: Chemical, clinical, and immunological studies on the products ofhuman
plasma fractionation. XII. The use of concentrated normal human serum gammaglobulin (human immune serum
globulin) in the prevention and attenuation of measles. J Clin Invest 23: 541, 1944
36. Berkovich S, Starr S: Use of live-measles-virus vaccine to abort an expected outbreak of measles within a closed
population. N Engl J Med 269: 75, 1963
37. SchiffGM: Titered lots ofimmune globulin (Ig). Efficacy in the prevention ofrubella. Am J Dis Child 118: 322, 1969
38. Doege TC, Kim KS: Studies of rubella and its prevention with immune globulin. JAMA 200: 584, 1967
39. Studies of the effect of immunoglobulin on rubella in pregnancy: report of the Public Health Laboratory Service
Working Party on Rubella. Br Med J 2: 497, 1970
40. Green RH, Balsamo MR, Giles JP, et al: Studies ofthe natural history and prevention of rubella. Am J Dis Child
110: 348, 1965
41. Ross AH: Modification ofchicken pox in family contacts by administration of gamma globulin. N Engl J Med 267:
369, 1962
42. Brunell PA, Ross A, Miller LH, et al: Prevention ofvaricella by zoster immune globulin. N Engl J Med 280: 1191,
1969
43. Brunell PA, Gershon AA, Hughes WT, et al: Prevention of varicella in high risk children: a collaboratory study.
Pediatrics 50: 718, 1972ANTIVIRAL THERAPY 527
44. Gershon AA, Steinberg S, Brunell PA: Zoster immune globulin: a further assessment. N Engl J Med 290: 243, 1974
45. Judelsohn RG, Meyers JD, Ellis RJ, et al: Efficacy of zoster immune globulin. Pediatrics 53: 476, 1974
46. Brunell PA, Gershon AA: Passive immunization against varicella-zoster infections and other modes of therapy. J
Infect Dis 127: 415, 1973
47. Reed D, Brown G, Merrick R, et al: A mumps epidemic on St. George Island, Alaska. JAMA 199: 967, 1967
48. Gellis SS, McGuinness AC, Peters M: A study on the prevention of mumps orchitis by gamma globulin. Am J Med
Sci 210: 661, 1945
49. Ranbar AC: Mumps: use ofconvalescent serum in treatment and prophylaxis oforchitis. Am J Dis Child 71: 1, 1946
50. Teissier P: De la contagiosit6 et de l'6pidemiologie de la fievre ourlineene: saprophylaxiegdneraleet saprophylaxie
serique. Bull MMd Paris 39: 349, 1925
51. De Lavergue V, Florentin P: Convalescent serum in prevention of orchitis in mumps. Bull Acad med 93: 362, 1925
52. Bailey WH, Haerem AT: Some observations on the efficacy ofconvalescent mumps serum. Mil Surg 90: 134, 1942
53. Kempe CH, Berge TO, England B: Hyperimmune vaccinal gamma globulin: source, evaluation, and use in
prophylaxis and therapy. Pediatrics 18: 177, 1956
54. Kempe Cil, Bowles G, Meiklejohn G, et al: The use ofvaccinia hyperimmune gamma-globulin in the prophylaxis of
smallpox. Bull WHO 25: 41, 1961
55. Kempe CH: Studies on smallpox and complications of smallpox vaccination. Pediatrics 26: 176, 1960
56. Lundstrom R: Complications of smallpox vaccination and their treatment with vaccinia immune gamma globulin. J
Pediatr 49: 129, 1956
57. Fulginiti VA, Kempe CH, Hathaway WE, et al: Progressive vaccinia in immunological deficient individuals. In
Immunologic deficiency diseases in man. Birth defects original article series no 14, no 1, Bergsma D, editor. New
York: The National Foundation, pp 129-145, 1968
58. Prince AM, Szmuness W, Woods KR, et al: Antibody against serum-hepatitis antigen: prevalence and potential use
as immune serum globulin in prevention of serum-hepatitis infections. N Engl J Med 285: 933, 1971
59. Krugman S: Effect of human immune serum globulin on infectivity of hepatitis A virus. J Infect Dis 134: 70, 1976
60. Silverberg M, Neumann PZ: Infectious hepatitis: gamma-globulin prophylaxis in a community outbreak. Am J Dis
Child 119: 117, 1970
61. Drake ME, Ming C: Gamma globulin in epidemic hepatitis: comparative value oftwo dosage levels, apparently near
the minimal effective level. JAMA 155: 1302, 1954
62. Stokes J Jr, Neefe JR: The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 127: 144,
1945
63. Stokes J Jr, Farquhar JA, Drake ME, et al: Infectious hepatitis: length of protection by immune serum globulin
(gamma globulin) during epidemics. JAMA 147: 714, 1951
64. Krugman S, Giles JP, Hammond J: Viral hepatitis type B (MS-2 strain). Prevention with specific hepatitis B immune
serum globulin. JAMA 218: 1665, 1971
65. Ginsberg AL, Conrad ME, Bancroft WH, et al: Prevention of endemic HAA-positive hepatitis with gamma
globulin. Use of a simple radioimmune assay to detect HAA. N Engl J Med 286: 562, 1972
66. Krugman S, Giles JP: Viral hepatitis, type B (MS-2-strain). Further observations on natural history and prevention.
N Engl J Med 288: 755, 1973
67. Kohler PF, Dubois RS, Merrill DA, et al: Prevention ofchronic neonatal hepatitis B virus infection with antibody
to the hepatitis surface antigen. N Engl J Med 291: 1378, 1974
68. Desmyter J, Bradburne AF, Vermylen C, et al: Hepatitis-B immunoglobulin in prevention of HBS antigenaemia in
haemodialysis patients. Lancet 2: 377, 1975
69. Szmuness W, Prince AM, Goodman M, et al: Hepatitis B immune serum globulin in prevention ofnonparenterally
transmitted hepatitis B. N Engl J Med 290: 701, 1974
70. Redeker AG, Mosley,JW, Gocke DJ, et al: Hepatitis B immune globulin as a prophylactic measure for spouses
exposed to acute type B hepatitis. N Engl J Med 293: 1055, 1975
71. Prince AM, Szmuness W, Mann MK, et al: Hepatitis B "immune" globulin: effectiveness in prevention of dialysis-
associated hepatitis. N Engl J Med 293: 1063, 1975
72. Grady GF, Lee VA: Prevention of hepatitis from accidental exposure among medical personnel. N Engl J Med 293:
1067, 1975
73. Feinstone SM, Kapikian AZ, Purcell RH, et al: Transfusion-associated hepatitis not due to viral hepatitis type A or
B. N Engl J Med 292: 767, 1975
74. Alter HJ, Purcell RH, Holland PV, et al: Clinical and serological analysis oftransfusion-associated hepatitis. Lancet
2: 838, 1975
75. Knodell RG, Conrad ME, Ginsberg AL, et al: Efficacy ofprophylactic gamma-globulin in preventing non-A, non-B
post-transfusion hepatitis. Lancet 1: 557, 1976
76. Davies WL, Grunert RR, Haff RF, et al: Antiviral activity of I-adamantanamine (amantadine). Science 144: 862,
1964528 HANS STALDER
77. Cochran KW, Maassab HF, Tsunoda A, et al: Studies on antiviral activity ofamantadine hydrochloride. Ann NY
Acad Sci 130: 432, 1965
78. Solovyov VN, Tolmacheva NS: Therapeutic effect ofadamantanamine aerosol in experimental influenza infection in
white mice. Acta virol 11: 482, 1967
79. Smorodintsev AA, Zlydnikov DM, Kiseleva AM, et al: Evaluation ofamantadine in artificially induced A2 and B
influenza. JAMA 213: 1448, 1970
80. Togo Y, Hornick RB, Dawkins AT: Studies on induced influenza in man: I. Double blind studies designed to assess
prophylactic efficacy of amantadine hydrochloride against A2/Rockville / 1/65 strain. JAMA 203: 1089, 1968
81. Jackson GG, Muldoon RL, Akers LW: Serological evidence for prevention of influenzal infection in volunteers by
an anti-influenzal drug adamantanamine hydrochloride. Antimicrob Agents Chemother 3: 703, 1963
82. Oker-Blom N, Hovi T, Leiniki P, et al: Protection ofman from natural infection with influenza A2 Hong Kongvirus
by amantadine: a controlled field trial. Br Med J 3: 676, 1970
83. O'Donoghue JM, Ray CG, Terry DW Jr, et al: Prevention ofnosocomial influenza infection with amantadine. Am J
Epidemiol 97: 276, 1973
84. Hornick RB, Togo Y, Mahler S, et al: Evaluation of amantadine hydrochloride in the treatment of A2 influenzal
disease. Bull WHO 41: 671, 1969
85. Togo Y, Hornick RB, Felitti VJ, et al: Evaluation of therapeutic efficacy of amantadine in patients with naturally
occurring A2 influenza. JAMA 211: 1149, 1970
86. Wingfield WL, Pollack D, Grunert RR: Therapeutic efficacy of amantadine HCI and rimantadine HCI in naturally
occurring influenza A2 respiratory illness in man. N Engl J Med 281: 579, 1969
87. Little JW, Hall WJ, Douglas RG, et al: Amantadine effect on peripheral airways abnormalities in influenza. A study
in 15 students with natural influenza A infection. Ann Intern Med 85: 177, 1976
88. Galbraith AW, Oxford JS, Schild GC, et al: Study of I-adamantanamine hydrochloride used prophylactically
during the Hong Kong influenza epidemic in the family environment. Bull WHO 41: 677, 1969
89. Schulman JL: Effect of I-amantanamine hydrochloride (amantadine HCI) and methyl-l-adamantanethylamine
(rimantadine HCI) on transmission of influenza virus infection in mice. Proc Soc Exp Biol Med 128: 1173, 1968
90. Tsunoda A, Maassab HF, Cochran KW, et al: Antiviral activity of a -methyl-I-adamantanemethylamine hydroch-
loride. Antimicrob Agent Chemother 5: 553, 1965
91. Dawkins AT, Gallayer LR, Togo Y, et al: Studies on induced influenza in man. II. Double blind study designed to
assess the prophylactic efficacy of an analogue of amantadine hydrochloride. JAMA 203: 1095, 1968
92. Bloch A: The structure of nucleosides in relation to their biological and biochemical activity: a summary. Ann NY
Acad Sci 255: 576, 1975
93. Bennett LL Jr, Shannon WM, Allan PW, et al: Studies on the biochemical basis for the antiviral activities of some
nucleoside analogs. Ann NY Acad Sci 255: 342, 1975
94. Kaufman HE, Martola EL, Dohlman CH: Use of 5-iodo-2'-deoxyuridine (IDU) in treatment of herpes simplex
keratitis. Arch Ophthal 68: 235, 1962
95. Prusoff WH, Bakhle YS, McCrea JF: Incorporation of 5-iodo-2'-deoxyuridine into the deoxyribonucleic acid of
vaccinia virus. Nature 199: 1310, 1963
96. Kaplan AS, Ben-Porat T: Differential incorporation of iododeoxyuridine into the DNA of pseudorabies virus-
infected and noninfected cells. Virology 31: 734, 1967
97. Renis HE, Buthala DA: Development of resistance to antiviral drugs. Ann NY Acad Sci 130: 343, 1965
98. Kaufman HE: Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine. Proc Soc Exp Biol Med 109: 251,
1962
99. Kern ER, Overall JC, Glasgow LA: Herpesvirus hominis infection in newborn mice. I. An experimental model and
therapy with iododeoxyuridine. J Infect Dis 128: 290, 1973
100. Lerner AM, Bailey EJ: Concentration of idoxuridine in serum, urine and cerebrospinal fluid of patients with
suspected herpesvirus hominis encephalitis. J Clin Invest 51: 45, 1972
101. Calabresi P, Cardoso SS, Finch SC, et al: Initial clinical studies with 5-iodo-2'-deoxyuridine. Cancer Res 21: 550,
1961
102. Percy DH, Hatch LA: Experimental infection with herpes simplex virus type 2 in newborn rats: effect of treatment
with iododeoxyuridine and cytosine arabinoside. J Infect Dis 132: 256, 1975
103. Marks MI: Evaluation offourantiviral agents in the treatment ofherpes simplex encephalitis in a rat model. J Infect
Dis 131: 11, 1975
104. Kaufman HE: Symposium: chemotherapy of herpes keratitis. Invest Ophthal 2: 504, 1963
105. Maxwell E: Treatment ofcorneal disease with 5-iodo-2'-deoxyuridine (IDU): clinical evaluation of 500 cases. Am J
Ophthal 55: 237, 1963
106. Hughes WF: Treatment of herpes simplex keratitis: a review. Am J Ophthal 67: 313, 1969
107. MacCallum FO, Juel-Jensen BE: Herpes simplex virus skin infection in man treated with idoxuridine in dimethyl
sulphoxide. Results of double-blind controlled trial. Br Med J 2: 805, 1966ANTIVIRAL THERAPY 529
108. Boston interhospital virus study group and the NIAID-sponsored cooperative antiviral clinical study: Failure of
high dose 5-iodo-2'-deoxyuridine in the therapy of herpes simplex virus encephalitis. Evidence of unacceptable
toxicity. N Engi J Med 292: 599, 1975
109. Prusoff WH, Bakhle YS, Sekely L: Cellular and antiviral effects of halogenated deoxyribonucleosides. Ann NY
Acad Sci 130: 135, 1965
110. Rowe WP, Lowy DR, Teich N, et al: Some implications of the activation of murine leukemia virus by halogenated
pyrimidines. Proc Nat Acad Sci USA 69: 1033, 1972
Ill. Graham FL, Whitmore GF: Studies in mouse L-cells on the incorporation of 1- 3 -D-arabinofuranosylcytosine into
DNA and on inhibition of DNA polymerase by 1-,1-D-arabinofuranosylcytosine 5'-triphosphate. Cancer Res 30:
2636, 1970
112. Kaplan AS, Brown McK, Ben-Porat T: Effect of 1-13 -D-arabinofuranosylcytosine on DNA synthesis. I. In normal
rabbit kidney cell cultures. Mol Pharmacol 4: 131, 1968
113. Buthala DA: Cell culture studies on antiviral agents: I. Action ofcytosine arabinoside and some comparisons with 5-
iodo-2-deoxyuridine. Proc Soc Exp Biol Med 115: 69, 1964
114. Ben-Porat T, Brown McK, Kaplan AS: Effect of 1-,B-D-arabinofuranosylcytosine on DNA synthesis. II. in rabbit
kidney cells infected with herpes viruses. Mol Pharmacol 4: 139, 1968
115. Elliot GA, Schut AL: Studies with cytarabine HCI (CA) in normal eyes of man, monkey and rabbit. Am J Ophthal
60: 1074, 1965
116. Creasey WA, Papac RJ, Markiw ME, et al: Biochemical and pharmacological studies with 1-1B-D arabinofurano-
sylcytosine in man. Biochem Pharmacol 15: 1417, 1966
117. Ho DHW, Frei E III: Clinical pharmacology of 1-1 -D-arabinofuranosylcytosine. Clin Pharmacol 14: 1405, 1965
118. Stevens DA, Jordan GW, Waddell TF, et al: Adverse effect of cytosine arabinoside on disseminated zoster in a
controlled trial. N Engl J Med 289: 873, 1973
119. Davis CM, Van Dersarl JV, Coltman CA: Failure ofcytarabine in varicella-zoster infections. JAMA224:122, 1973
120. Schimpff SC, Fortner CL, Greene WH, et al: Cytosine arabinoside for localized herpes zoster in patients with
cancer: failure in a controlled trial. J Infect Dis 130: 673, 1974
121. Monsur KA, Hossain MS, Huq F, et al: Treatment ofvariola major with cytosine arabinoside. J Infect Dis 131: 40,
1975
122. Kaufman HE, Capella JA, Maloney ED, et al: Corneal toxicity ofcytosine arabinoside. Arch Ophthal 72: 535, 1964
123. Pavan-Langston D, Buchanan RA, Alford CA, editors: Adenine arabinoside: an antiviral agent. New York:
Raven Press, 1975
124. Schabel FM: The antiviral activity of 9-,8-D-arabinofuranosyl adenine (Ara A). Chemother 13: 321, 1968
125. York JL, Le Page GA: A proposed mechanism for the action of9-13 -D-arabinofuranosyladenine as an inhibitor of
the growth of some ascites cells. Can J Biochem 44: 19, 1966
126. Plunkett W, Cohen SS: Metabolism of9-,1 -D-arabinofuranosyladenine by mouse fibroblasts. Cancer Res 35: 415,
1975
127. Nesburn AB, Robinson C, Dickinson R: Adenine arabinoside effect on experimental idoxuridine-resistant herpes
simplex infection. Invest Ophthal 13: 302, 1974
128. Sloan BJ: Adenine arabinoside: chemotherapy studies in animals. In Adenine arabinoside: an antiviral agent.
Pavan-Langston D, Buchanan RA, Alford CA, editors. New York: Raven Press, 1975, pp 45-94
129. Connor JD, Sweetman L, Carey S, et al: Susceptibility in vitro ofseveral large DNA viruses to the antiviral activity
of adenine arabinoside and its metabolite hypoxanthine arabinoside: relation to human pharmacology. In Adenine
arabinoside: an antiviral agent. Pavan-Langston D, Buchanan RA, Alford CA, editors, New York: Raven Press,
1975, pp 177-196
130. Kinkel AW, Buchanan RA: Human pharmacology. In Adenine arabinoside: anantiviral agent. Pavan-Langston D,
Buchanan RA, Alford CA, editors. New York: Raven Press, 1975, pp 197-204
131. Bryson Y, Connor JD, Sweetman L, et al: Determination ofplaque inhibitory activity ofadenine arabinoside(9-13 -
D-arabinofuranosyladenine) for herpes-viruses using an adenosine deaminase inhibitor. Antimicrob Agents Chem-
other 6: 98, 1974
132. Dresne AJ, Seamans ML: Evidence of the safety and efficacy of adenine arabinoside in the treatment of herpes
simplex epithelial keratitis. In Adenine arabinoside: an antiviral agent. Pavan-Langston D, Buchanan RA, Alford
CA, editors. New York: Raven Press, 1975, pp 381-392
133. Abel R Jr, Kaufman HE, Sugar J: Effect of intravenous adenine arabinoside on herpes simplex keratouveitis in
humans. In Adenine arabinoside: an antiviral agent. Pavan-Langston D, Buchanan RA, Alford CA, editors. New
York: Raven Press, 1975, pp 393-400
134. Whitley RJ, Ch'ien, LT, Dolin R, et al: Adenine arabinoside therapy of herpes zoster in the immunosuppressed,
NIAID collaborative antiviral study. N Engl J Med 294: 1193, 1976
135. Ch'ien LT, Cannon NJ, Charamella LJ, et al: Effect ofadenine arabinoside on severe Herpesvirus hominis infection
in man. J Infect Dis 128: 658, 1973530 HANS STALDER
136. Whitley RJ, Ch'ien LT, Nahmias AJ, et al: Adenine arabinoside therapy ofneonatal herpetic infections. In Adenine
arabinoside: an antiviral agent. Pavan-Langston D, Buchanan RA, Alford CA, editors. New York: Raven Press,
1975, pp 225-236
137. Ross AH, Julia A, Balakrishnan C: Toxicity of adenine arabinoside in humans. J Infect Dis 133: (Suppl.), A192,
1976
138. Koplan JP, Monsur KA, Foster SO, et al: Treatment ofvariola majorwith adenine arabinoside. J Infect Dis 131: 34,
1975
139. Adams HG, Benson EA, Alexander ER, et al: Genital herpetic infection in men and women: clinical course and
effect of topical application of adenine arabinoside. J Infect Dis 133: (Suppl.), A151, 1976
140. Ch'ien LT, Cannon NJ, Whitley RJ, et al: Effect ofadenine arabinoside on cytomegalovirus infections. J Infect Dis
130: 32, 1974
141. Rytel MW, Kauffman HM: Clinical efficacy ofadenine arabinoside in therapy ofcytomegalovirus infections in renal
allograft recipients. J Infect Dis 133: 202, 1976
142. Hyndiuk RK, Kaufman HE: Newer compounds in therapy of herpes simplex keratitis. Arch Ophthal 78: 600, 1967
143. Sidwell RW, Huffman JH, Khare GP, et al: Broad-spectrum antiviral activity of virazole: 1-,B-D-ribofuranosyl-
1,2,4-triazole-3-carboxamide. Science 177: 705, 1972
144. Hamre D, Bernstein I, Donovick R: Activity ofp-aminobenzaldehyde,3-thiosemicarbazone on vaccinia virus in the
chick embryo and in the mouse. Proc Soc Exp Biol Med 73: 275, 1950
145. Thompson RL, Minton SA, Jr, Officer JE, et al: Effect of heterocyclic and other thiosemicarbazones on vaccinia
infection in the mouse. J Immunol 70: 229, 1953
146. Bauer DJ, Apostolov K, Selway JWT: Activity of methisazone against RNA viruses. Ann NY Acad Sci 173: 314,
1970
147. Easterbrook KB: Interference with the maturation of vaccinia virus by isatin /3 -thiosemicarbazone. Virology 17:
245, 1962
148. Woodson B, Joklik WK: The inhibition of vaccinia virus multiplication by isatin-/3 -thiosemicarbazone. Proc Nat
Acad Sci USA 54: 946, 1965
149. Magee WE, Bach MK: Biochemical studies on the antiviral activities ofthe isatin-p -thiosemicarbazones. Ann NY
Acad Sci 130: 80, 1965
150. Bauer DJ, St Vincent L, Kempe CH, et al: Prophylactic treatment of smallpox contacts with N-methylisatin,B -
thiosemicarbazone (compound 33T57, Marboran). Lancet 2: 494, 1963
151. Bauer DJ, St Vincent L, Kempe CH, et al: Prophylaxis ofsmallpox with methisazone. Am J Epidemiol 90:130, 1969
152. Heiner GG, Fatima N, Russell PK, et al: Field trials of methisazone as a prophylactic agentagainst smallpox. Am J
Epidemiol 94: 435, 1971
153. Rao AR, Jacobs ES, Kamalakshi S, et al: Chemoprophylaxis and chemotherapy in variola major. I. An assessment
of CG 662 and Marboran in prophylaxis of contacts of variola major. Indian J Med Res 57: 477, 1969
154. Rao AR, Jacobs ES, Kamalakshi S, et al: Chemoprophylaxis and chemotherapy in variola major. Part II.
Therapeutic assessment of CG 662 and Marboran in treatment ofvariola major in man. Indian J Med Res 57: 484,
1969
155. Bauer DJ: Clinical experience with the antiviral drug MarboranR (1-methylisatin 3-thiosemicarbazone). Ann NY
Acad Sci 130: 110, 1965
156. Jaroszynska-Weinberger B: Treatment with methisazone ofcomplications following smallpox vaccination. Arch Dis
Child 45: 573, 1970
157. Green RH, Opton EM: Photosensitization of tissue culture cells and its effect on viral plaque formation. Proc Soc
Exp Biol Med 102: 519, 1959
158. Hiatt CW, Kaufman E, Helprin JJ, et al: Inactivation of viruses by photodynamic action of toluidine blue. J
Immunol 84: 480, 1960
159. Wallis C, Trulock S, Melnick JL: Inherent photosensitivity of herpes virus and other enveloped viruses. J Gen
Virology 5: 53, 1969
160. Moore C, Wallis C, Melnick JL, et al: Photodynamic treatment of herpes keratitis. Infect and Immun 5: 169, 1972
161. Varnell ED, Kaufman HE: Photodynamic inactivation with proflavine: quantitative comparison with iodo-
deoxyuridine. Infect and Imm 7: 518, 1973
162. Rapp F, Li JLH, Jerkofsky M: Transformation ofmammalian cells by DNA-containing viruses following photody-
namic inactivation. Virology 55: 339, 1973
163. Felber TD, Smith EB, Knox JM, et al: Photodynamic inactivation of herpes simplex, report of a clinical trial.
JAMA 223: 289, 1973
164. Myers MG, Oxman MN, Clark JE, et al: Failure of neutral-red photodynamic inactivation in recurrent herpes
simplex virus infections. N Engl J Med 293: 945, 1975
165. Taylor PK, Doherty NR: Comparison ofthe treatment ofherpes genitalis in men with proflavine photoinactivation,
idoxuridine ointment, and normal saline. Br J Vener Dis 51: 125, 1975ANTIVIRAL THERAPY 531
166. Isaacs A, Lindenmann J: Virus interference. I. The interferon. Proc Roy Soc Series B 147: 258, 1957
167. Grossberg SE: The interferons and their inducers: molecular and therapeutic considerations. N Engl J Med 287: 13,
79, 122, 1972
168. Friedman RM: Interferon research in the Red Queen's kingdom. Arch Pathol 98: 73, 1974
169. Knight E: Interferon: purification and initial characterization from human diploid cells. Proc Nat Acad Sci USA 73:
520, 1976
170. De Clercq E, Merigan TC: Induction of interferon by nonviral agents. Arch Intern Med 126: 94, 1970
171. Marcus PI, Salb JM: Molecular basis of interferon action: inhibition of viral RNA translation. Virology 30: 502,
1966
172. Friedman RM, Metz DH, Esteban RM, et al: Mechanisms of interferon action: inhibition of viral messenger
ribonucleic acid translation in L-cell extracts. J Virol 10: 1184, 1972
173. Oxman MN, Levin MJ: Interferon and transcription ofearly virus-specific RNA in cells infected with simian virus
40. Proc Nat Acad Sci 68: 299, 1971
174. Desmyter J, Rawls WE, Melnick JL: Sensitivity of rabbit cells to primate interferons. Ann NY Acad Sci 173: 492,
1970
175. Chany C, Ankel H, Bourgeade MF: Interferon cell receptor interactions: chapter 15. In Antiviral mechanisms:
perspectives in virology. IX. Pollard M, editor. New York: Academic Press, 1975, pp 269-277
176. Glasgow LA, Hanshaw JB, Merigan TC, et al: Interferon and cytomegalovirus in vivo and in vitro. Proc Soc Exp
Biol Med 125: 843, 1967
177. Green JA, Cooperbrand SR, Kibrick S: Immune specific induction of interferon production in cultures of human
blood lymphocytes. Science 164: 1415, 1969
178. Cate, TR, Douglas G Jr, Couch RB: Interferon and resistance to upper respiratory virus illness. Proc Soc Exp Biol
Med 131: 631, 1969
179. Stevens DA, Ferrington RA, Jordan GW, et al: Cellular events in zoster vesicles: relation to clinical course and
immune response. J Infect Dis 131: 509, 1975
180. Armstrong RW, Gurwith MJ, Waddell D, et al: Cutaneous interferon production in patients with Hodgkin's disease
and other cancers infected with varicella or vaccinia. N Engl J Med 283: 1182, 1970
181. Gresser I, Tovey MG, Bandu MT, et al: Role of interferon in the pathogenesis of virus diseases in mice as
demonstrated by the use of anti-interferon serum. J Exp Med 144: 1305, 1976
182. Lindahl-Magnusson P, Leary P, Gresser I: Interferon inhibits DNA synthesis induced in mouse lymphocyte
suspension by phytohaemagglutinin or by allogenic cells. Nature N Biol 237: 120, 1972
183. Paucker K, Cantell K, Henle W: Quantitative studies on viral interference in suspended L-cells. Ill. Effect of
interfering viruses and interferon on the growth rate of cells. Virology 17: 324, 1962
184. Knight E Jr: Antiviral and cell growth inhibitory activities reside in the same glycoprotein of human fibroblast
interferon. Nature 262: 302, 1976
185. De Maeyer E, De Maeyer-Guignard J, Vandeputte M: Inhibition by interferon ofdelayed-type hypersensitivity in
the mouse. Proc Soc Acad Sci USA 72: 1753, 1975
186. Hirsch MS, Ellis DA, Black PH, et al: Immunosuppressive effects ofan interferon preparation in vivo. Transplanta-
tion 17: 234, 1974
187. Chester TJ, Paucker K, Merigan TC: Suppression of mouse antibody producing spleen cells by various interferon
preparations. Nature 246: 92, 1973
188. Gresser I, Tovey MG, Maury C, et al: Lethality ofinterferon preparations for newborn mice. Nature 258: 76, 1975
189. Sehgal PB, Tamm I, Vilcek J: Human interferon production: superinduction by 5,6-dichloro-1-,B-D-
ribofuranosylbenzimidazole. Science 190: 282, 1975
190. Em8di G, Rufli T, Just M, et al: Human interferon therapy for herpes zoster in adults. Scand J Infect Dis 7: 1, 1975
191. Jordan GW, Fried RP, Merigan TC: Administration of human leukocyte interferon in herpes zoster. 1. Safety,
circulating antiviral activity, and host responses to infection. J Infect Dis 130: 56, 1974
192. Greenberg HB, Pollard RB, Lutwick LI, et al: Effect of human leukocyte interferon on hepatitis Bvirus infection in
patients with chronic active hepatitis. N Engl J Med 295: 517, 1976
193. Merigan TC, Jordan GW, Fried RP: Clinical utilization of exogenous human interferon. Chapter 14. In Antiviral
mechanisms: perspectives in virology. IX. Pollard M, editor. New York: Academic Press, 1975, pp 249-268
194. Solovev VD: The results ofcontrolled observations on the prophylaxis ofinfluenza with interferon. Bull WHO 41:
683, 1969
195. Merigan TC, Reed SE, Hall TW, et al: Inhibition ofrespiratory virus infection by locally applied interferon. Lancet
1: 563, 1973
196. Kaufman HE, Meyer RF, Laibson PR: Human leukocyte interferon for the prevention of recurrences of herpetic
keratitis. J Infect Dis 133 (Suppl.): A165, 1976
197. Hill DA, Baron S, Perkins JC, et al: Evaluation of an interferon inducer in viral respiratory disease. JAMA 209:
1179, 1972532 HANS STALDER
198. Stanley ED, Jackson GG, Dirda VA,.et al: Effect of a topical interferon inducer on rhinovirus infections in
volunteers. J Infect Dis 133 (Suppl.): A121, 1976
199. Panusarn C, Stanley ED, Dirda V, et al: Prevention of illness from rhinovirus infection by a topical interferon
inducer. N Engl J Med 291: 57, 1974
200. Douglas RG Jr: Effect of induced interferon in experimental rhinovirus infection in volunteers. Infect Immunity 9:
506, 1974
201. Christie AB: Infectious diseases: Epidemiology and clinical practice, 2nd edition. Edinburgh: Churchill Livingstone,
1974, p 395
202. Recommendation of the Public Health Service advisory committee on immunization practices: Immune serum
globulin for protection against viral hepatitis. Morbidity and Mortality Weekly Report 17: 194, 1968
203. Kern AB, Schiff BL: Smallpox vaccination in the management of recurrent herpes simplex: a controlled evaluation.
J Invest Dermatol 33: 99, 1959
204. Kern AB, Schiff BL: Vaccine therapy in recurrent herpes simplex. Arch Dermatol Syphil 89: 844, 1964
205. Nahmias AJ, Josey WE, Naib ZM, et al: Perinatal risk associated with maternal genital herpes simplex virus
infection. Am J Obst Gynecol 110: 825, 1971
206. Amstey MS, Monif GRG: Genital herpesvirus infection in pregnancy. Obst Gynecol 44: 394, 1974
207. Johnson RT: Treatment of herpes simplex virus encephalitis. Arch Neurol 27: 97, 1972
208. Laibson PR: Current therapy of herpes simplex virus infection of the cornea. Int Ophthal Clin 13: 39, 1973
209. Pavan-Langston D: New developments in the therapy of ocular herpes simplex. Int Ophthal Clin 13: 53, 1973
210. Schwab RS, Poskanzer DC, England AC Jr, et al: Amantadine in Parkinson's disease, Review of more than two
years' experience. JAMA 222: 792, 1972
211. Bleidner WE, Harmon JB, Hewes WE, et al: Absorption, distribution and excretion ofamantadine hydrochloride. J
Pharmacol Exp Ther 150: 484, 1965
212. Recommendation of the Public Health Service advisory committee on immunization practices: Measles Vaccines.
Ann Intern Med 76: 101, 1972
213. Greenberg M, Appelbaum E, Pellitteri 0, et al: Measles encephalitis. II. Treatment with gamma globulin. J Pediat
46: 648, 1955
214. Lerner AM: Guide to immunization against mumps. J Infect Dis 122: 116, 1970
215. Werner CA: Mumps orchitis and testicular atrophy. II. A factor in male sterility. Ann Intern Med 32: 1075, 1950
216. Klemola E, Somer P: Corticotropin och cortison vid parotitorchit. Nordisk Medicin 9: 1128, 1956
217. Kocen RS, Critchley E: Mumps epididymo-orchitis and its treatment with cortisone: report of a controlled trial. Br
Med J 2: 20, 1961
218. Recommendation of the Public Health Service advisory committee on immunization practices: Rabies, Morbidity
and Mortality Weekly Report 25: 403, 1976
219. Corey L, Hattwick MAW: Treatment of persons exposed to rabies. JAMA 232: 272, 1975
220. Kaplan MM, Cohen D, Koprowski H, et al: Studies on the local treatment of wounds for the prevention of rabies.
Bull WHO 26: 765, 1962
221. Buescher EL: Behaviour of rubella virus in adult populations. Arch Ges Virusforsch 16: 470, 1965
222. Goldstein JA, NeffJM, Lane JM, et al: Smallpox vaccination reactions, prophylaxis, and therapy ofcomplications.
Pediatrics 55: 342, 1975
223. O'Connell CJ, Karzon DT, Barron AL, et al: Progressive vaccinia with normal antibodies: a case possibly due to
deficient cellular immunity. Ann Intern Med 60: 282, 1964
224. Ruben FL, Lane SM: Ocular vaccinia. Arch Ophthal 84: 45, 1970
225. Zoster immune globulin available. Morbidity and Mortality Weekly Report 25: 86, 1976
226. Juel-Jensen BE, MacCallum FO, Mackenzie AMR, et al: Treatment of zoster with idoxuridine in dimethyl
sulfoxide. Results of two double-blind controlled trials. Br Med J 4: 776, 1970
227. Eaglestein WH, Katz R, Brown JA: The effects of early corticosteroid therapy on the skin eruption and pain of
herpes zoster. JAMA 211: 1681, 1970
228. Elliot FA: Treatment of herpes zoster with high doses of prednisone. Lancet 2: 610, 1964
Hans Stalder, M.D.
Department of Internal Medicine
Infectious Disease Division
University of Geneva Medical School
H6pital cantonal
1211 Geneva 4, Switzerland